Drug Approval And CommercializationZurzuvae, the first and only oral treatment specifically for postpartum depression, has been approved and is expected to show steady growth as it gains momentum in the healthcare industry.
Financial OutlookWith a strong cash position and anticipated funding, SAGE is well-prepared to support its operations and capitalize on Zurzuvae's launch and its promising pipeline, including SAGE-718 and SAGE-324.
Pipeline DevelopmentThe SAGE-718 cognitive impairment program represents a significant value-driver for SAGE, with a strong central nervous system pipeline poised for potential value creation in the near future.